UBS analyst Kevin Caliendo raised the firm’s price target on Alignment Healthcare (ALHC) to $18 from $17 and keeps a Neutral rating on the shares.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALHC:
- Alignment Healthcare Surpasses Q3 2025 Financial Expectations
- Alignment Healthcare: Strong Financial Performance and Strategic Growth Positioning Earns Buy Rating
- Alignment Healthcare reports Q3 EPS 2c, consensus (1c)
- Alignment Health Plan, Suvida Healthcare partner for bilingual care
- Alignment Healthcare initiated with a Buy at Goldman Sachs